Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > HERE'S TO A SLEEPY & LAZY HOMEGROWN MESSAGE BOARD:

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Jan 08, 2022 9:15pm

86 Views

Post# 34296976

RE:HERE'S TO A SLEEPY & LAZY HOMEGROWN MESSAGE BOARD:

Ouch, rough fact sheet! Thanks for posting so others understand why not to invest. Management takes a company from .58 down to .04 and then conduct a 100-1 consolidation....

Now they have 4 trials planned even though they couldn't execute the last two, can't imagine the dilution with a full warrant to come. Ouch again

<< Previous

Bullboard Posts

Next >>

First Helium advances winter drilling program with Leduc Anomaly test well